SCHEMBL121884

SCHEMBL121884

CC(=O)[C@H](C)NC(=O)[C@H](C)N

nearest known ligand 0.52

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
DPP4 P27487 3/20 0.52
DPP8 Q6V1X1 2/20 0.40
DPP7 Q9UHL4 2/20 0.40
PAX8 Q06710 1/20 0.39
CTRB1 P17538 5/20 0.38
SLC15A1 P46059 1/20 0.35
FAP Q12884 1/20 0.34
DPP9 Q86TI2 1/20 0.34
TAAR1 Q96RJ0 1/20 0.33
XIAP P98170 1/20 0.32
BIRC2 Q13490 1/20 0.32
MME P08473 1/20 0.31
ACE P12821 1/20 0.31
CPA1 P15085 1/20 0.31
ACE2 Q9BYF1 1/20 0.31
NOD1 Q9Y239 1/20 0.31
METAP2 P50579 3/20 0.31
METAP1 P53582 3/20 0.31
IDO1 P14902 2/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13598645 1.00 DPP4 (0.52) DPP4DPP8DPP7PAX8CTRB1
SCHEMBL23748421 1.00 DPP4 (0.52) DPP4DPP8DPP7PAX8CTRB1
SCHEMBL27395697 0.95 DPP4 (0.48) DPP4DPP8DPP7PAX8CTRB1
Acetic Acid SCHEMBL7446014 0.81 DPP4 (0.48) DPP4DPP8DPP7PAX8CTRB1
SCHEMBL12285707 0.81 DPP4 (0.55) DPP4DPP8DPP7FAPDPP9
SCHEMBL12522511 0.81 DPP4 (0.55) DPP4DPP8DPP7FAPDPP9
SCHEMBL14399462 0.81 DPP4 (0.55) DPP4DPP8DPP7FAPDPP9
SCHEMBL12946390 0.81 DPP4 (0.55) DPP4DPP8DPP7FAPDPP9
SCHEMBL19934697 0.80 DPP4 (0.52) DPP4DPP8DPP7PAX8CTRB1
SCHEMBL380600 0.80 DPP4 (0.52) DPP4DPP8DPP7PAX8CTRB1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2023078021-A1 BCMA MONOCLONAL ANTIBODY AND THE ANTIBODY-DRUG CONJUGATE HANGZHOU DAC BIOTECH CO., LTD. (CN) 2023-05-11 WO disclosed
EP-3901162-A1 GLUCOCORTICOID RECEPTOR AGONIST AND IMMUNOCONJUGATES THEREOF AbbVie Inc. (US) 2021-10-27 EP disclosed
WO-2020236817-A2 MCL-1 INHIBITOR ANTIBODY-DRUG CONJUGATES AND METHODS OF USE NOVARTIS AG (CH) 2020-11-26 WO disclosed
US-9428483-B2 Prodrug of fluorine-containing amino acid TAISHO PHARMACEUTICAL CO., LTD. (JP) 2016-08-30 US disclosed
US-20150306084-A1 ADENOSINE A1 AGONISTS FOR THE TREATMENT OF GLAUCOMA AND OCULAR HYPERTENSION BAYER IP GMBH (DE) 2015-10-29 US disclosed
US-9040566-B2 Adenosine A1 agonists for the treatment of glaucoma and ocular hypertension BAYER INTELLECTUAL PROPERTY GMBH (DE) 2015-05-26 US disclosed
US-20150141669-A1 PRODRUG OF FLUORINE-CONTAINING AMINO ACID TAISHO PHARMACEUTICAL CO., LTD. (JP) 2015-05-21 US disclosed
US-8513381-B2 Melanocortin analogs with antimicrobial activity FONDAZIONE IRCCS CA' GRANDA-OSPEDALE MAGGIORE POLICLINICO (IT) 2013-08-20 US disclosed
US-20130210797-A1 ADENOSINE A1 AGONISTS FOR THE TREATMENT OF GLAUCOMA AND OCULAR HYPERTENSION BAYER INTELLECTUAL PROPERTY GMBH (DE) 2013-08-15 US disclosed
US-20120058983-A1 Adenosine A1 agonists for the treatment of glaucoma and ocular hypertension BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2012-03-08 US disclosed
US-20120015873-A1 MELANOCORTIN ANALOGS WITH ANTIMICROBIAL ACTIVITY FONDAZIONE IRCCS CA' GRANDA - OSPEDALE MAGGIORE POLICLINICO (IT) 2012-01-19 US disclosed
US-20100081786-A1 Homogeneous Erythropoietin and Other Peptides and Proteins, Methods and Intermediates for Their Preparation NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2010-04-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100081786-A1 Homogeneous Erythropoietin and Other Peptides and Proteins, Methods and Intermediates for Their Preparation EPOR, LIFR, LNPEP DPP4 2891/4885DPP8 3824/4885DPP7 3144/4885
US-20150141669-A1 PRODRUG OF FLUORINE-CONTAINING AMINO ACID SLC1A2, SLC1A1, SLC1A3 DPP4 1717/4885DPP8 1393/4885DPP7 2162/4885
US-20120015873-A1 MELANOCORTIN ANALOGS WITH ANTIMICROBIAL ACTIVITY MC4R, MC3R, MC1R DPP4 109/4885DPP8 127/4885DPP7 78/4885
US-20130210797-A1 ADENOSINE A1 AGONISTS FOR THE TREATMENT OF GLAUCOMA AND OCULAR HYPERTENSION ADORA1, ADORA3, ADORA2A DPP4 1079/4885DPP8 829/4885DPP7 749/4885
US-20120058983-A1 Adenosine A1 agonists for the treatment of glaucoma and ocular hypertension ADORA1, ADORA3, ADORA2A DPP4 1079/4885DPP8 829/4885DPP7 749/4885
US-20150306084-A1 ADENOSINE A1 AGONISTS FOR THE TREATMENT OF GLAUCOMA AND OCULAR HYPERTENSION ADORA1, ADORA3, ADORA2A DPP4 1079/4885DPP8 829/4885DPP7 749/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.